Halozyme Therapeutics, Inc. (HALO) DCF Valuation

Halozyme Therapeutics, Inc. (HALO) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Halozyme Therapeutics, Inc. (HALO) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Streamline your analysis and improve precision with our (HALO) DCF Calculator! Equipped with real data from Halozyme Therapeutics, Inc. and customizable assumptions, this tool allows you to forecast, evaluate, and appraise (HALO) like a seasoned investor.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 196.0 267.6 443.3 660.1 829.3 853.9 879.2 905.3 932.2 959.8
Revenue Growth, % 0 36.53 65.67 48.91 25.62 2.97 2.97 2.97 2.97 2.97
EBITDA -56.6 153.0 259.0 315.5 451.9 322.8 332.4 342.3 352.4 362.9
EBITDA, % -28.86 57.16 58.43 47.8 54.5 37.81 37.81 37.81 37.81 37.81
Depreciation 4.1 3.3 3.0 49.6 84.9 37.1 38.2 39.3 40.5 41.7
Depreciation, % 2.08 1.23 0.67605 7.52 10.23 4.35 4.35 4.35 4.35 4.35
EBIT -60.6 149.7 256.0 265.9 367.1 285.7 294.2 302.9 311.9 321.2
EBIT, % -30.93 55.94 57.76 40.28 44.27 33.46 33.46 33.46 33.46 33.46
Total Cash 421.3 368.0 740.9 362.8 336.0 675.4 695.4 716.0 737.3 759.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 59.4 97.7 91.0 231.1 234.2
Account Receivables, % 30.33 36.52 20.52 35 28.24
Inventories 29.4 60.7 53.9 100.1 127.6 137.3 141.4 145.6 149.9 154.3
Inventories, % 14.98 22.7 12.16 15.17 15.39 16.08 16.08 16.08 16.08 16.08
Accounts Payable 6.4 1.9 1.5 17.7 11.8 14.4 14.9 15.3 15.8 16.2
Accounts Payable, % 3.28 0.72049 0.34761 2.68 1.42 1.69 1.69 1.69 1.69 1.69
Capital Expenditure -4.0 -2.5 -1.5 -4.8 -15.3 -10.1 -10.4 -10.7 -11.0 -11.3
Capital Expenditure, % -2.06 -0.93575 -0.32866 -0.72866 -1.84 -1.18 -1.18 -1.18 -1.18 -1.18
Tax Rate, % 19.16 19.16 19.16 19.16 19.16 19.16 19.16 19.16 19.16 19.16
EBITAT -60.6 149.4 414.9 215.9 296.8 263.9 271.7 279.8 288.1 296.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -143.0 76.0 429.7 90.6 329.8 260.9 288.3 296.9 305.7 314.7
WACC, % 9.39 9.39 9.39 9.23 9.23 9.33 9.33 9.33 9.33 9.33
PV UFCF
SUM PV UFCF 1,122.5
Long Term Growth Rate, % 3.50
Free cash flow (T + 1) 326
Terminal Value 5,590
Present Terminal Value 3,579
Enterprise Value 4,701
Net Debt 1,381
Equity Value 3,321
Diluted Shares Outstanding, MM 134
Equity Value Per Share 24.74

What You Will Gain

  • Pre-Populated Financial Model: Halozyme's actual data facilitates accurate DCF valuation.
  • Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
  • Immediate Calculations: Automatic updates provide real-time results as you make adjustments.
  • Investor-Ready Template: A polished Excel file crafted for professional-level valuation.
  • Customizable and Repeatable: Designed for adaptability, allowing for repeated use in detailed forecasts.

Key Features

  • Comprehensive Financial Data: Gain access to precise historical figures and future forecasts for Halozyme Therapeutics, Inc. (HALO).
  • Adjustable Projection Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins to fit your analysis.
  • Automated Financial Calculations: Instant updates for DCF, Net Present Value (NPV), and cash flow assessments.
  • User-Friendly Visualization: Intuitive charts and summaries to clearly present your valuation findings.
  • Designed for All Skill Levels: A straightforward layout tailored for investors, financial officers, and consultants alike.

How It Works

  • 1. Access the Template: Download and open the Excel file containing Halozyme Therapeutics, Inc.'s preloaded data.
  • 2. Adjust Parameters: Modify key inputs such as growth rates, WACC, and capital expenditures.
  • 3. View Results in Real-Time: The DCF model automatically calculates intrinsic value and NPV.
  • 4. Explore Scenarios: Evaluate various forecasts to analyze different valuation results.
  • 5. Present with Assurance: Share professional valuation insights to back your strategic decisions.

Why Choose This Calculator for Halozyme Therapeutics, Inc. (HALO)?

  • Accuracy: Utilizes real Halozyme financial data for precise calculations.
  • Flexibility: Allows users to easily adjust and experiment with various inputs.
  • Time-Saving: Eliminate the complexities of constructing a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
  • User-Friendly: Intuitive interface suitable for users with varying levels of financial modeling expertise.

Who Should Use This Product?

  • Investors: Accurately assess Halozyme Therapeutics’ fair value before making investment decisions.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Halozyme (HALO).
  • Consultants: Easily customize the template for valuation reports tailored to Halozyme (HALO) clients.
  • Entrepreneurs: Gain insights into the financial modeling practices of leading biotech companies like Halozyme (HALO).
  • Educators: Employ it as a teaching resource to illustrate valuation methodologies in the biotech sector.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Halozyme Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Halozyme Therapeutics, Inc. (HALO).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.